Clinical and Molecular Risk Factors of Anti-tubercular Therapy Induced Hepatitis.

J Clin Exp Hepatol

Department of Medicine, Maulana Azad Medical College, University of Delhi, New Delhi-02, India.

Published: June 2018

Background: This is a case-control study aimed at evaluating clinical as well as molecular risk factors for occurrence of ATT induced hepatitis in Northern Indian population.

Methods: 100 patients of tuberculosis were recruited from both Outdoor patient department and wards of Lok Nayak Hospital, New Delhi. 40 out of 100 patients who developed ATT induced hepatitis were taken as test group and 60 out of 100 patients who didn't develop liver dysfunction on ATT were taken as controls and studied and compared for clinical factors such as age, gender, nutritional status, HBsAg carrier, chronic hepatitis C and HIV infection. Molecular factors i.e. NAT2 acetylator status, GSTT1 and M1 null mutations were also determined in all of the patients in each group and compared.

Results: Mean body weight and serum albumin were significantly lower in the ATT induced hepatitis patients as compared to the control group. No preferential association was observed between age and gender with ATT induced hepatitis. HBsAg carrier (OR-6.5;  = 0.03), HIV infection (OR-5.1;  = 0.01), slow acetylator phenotype (OR-3.85;  = 0.02), GSTM1 null mutation (OR-2.72;  = 0.02) and GSTT1 null mutation (OR-3.12;  = 0.02) were found to be positively co-related to ATT induced hepatitis according to the univariate analysis. HBsAg carrier (OR-23.18;  = 0.01), HIV infection (OR-16.92;  = 0.02), Slow acetylator phenotype (OR-70.90;  = 0.001), GSTM1 null mutation (OR-37.03;  = 0.002) and GSTT1 null mutation (OR-8.19;  = 0.014) were also found to be independently increasing the risk of ATT induced hepatitis using multivariate analysis.

Conclusion: The present study established a positive co-relation between malnutrition, HBsAg carrier, HIV infection, NAT2 slow acetylators, GSTM1 null mutation, GSTT1 null mutation and ATT induced hepatitis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477131PMC
http://dx.doi.org/10.1016/j.jceh.2018.06.012DOI Listing

Publication Analysis

Top Keywords

induced hepatitis
32
att induced
28
null mutation
24
hbsag carrier
16
hiv infection
16
gstt1 null
16
100 patients
12
gstm1 null
12
hepatitis
9
molecular risk
8

Similar Publications

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally due to HCC late diagnosis and limited treatment options. MiRNAs (miRNAs) emerged as potential biomarkers for various diseases, including HCC. However, the value of miRNA-101 as a serum biomarker for HCV-induced HCC has not been fully investigated.

View Article and Find Full Text PDF

MIF/CD74 axis in hepatic stellate cells mediates HBV-related liver fibrosis.

Int Immunopharmacol

January 2025

Department of Transplantation Immunology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin Province 130061, China. Electronic address:

Chronic hepatitis B virus (HBV) infection is a major risk factor for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Despite advances in understanding HBV-related liver diseases, effective therapeutic strategies remain limited. Macrophage migration inhibitory factor (MIF) has been implicated in various inflammatory and fibrotic conditions, but its role in HBV-induced liver fibrosis has not been fully explored.

View Article and Find Full Text PDF

CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.

Cancer Immunol Immunother

January 2025

Department of Dermatology and National Center for Tumor Diseases (NCT), Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.

Cytomegalovirus (CMV) infection or reactivation in immune-compromised individuals can lead to a wide range of severe complications including hepatitis. However, its relation with immune checkpoint inhibitors (ICIs) induced hepatitis (ICI-hepatitis) and tumor responses in advanced melanoma patients remains unclear. Hundred and ninety metastatic cutaneous melanoma patients (mCM) who received ICI treatment, with CMV IgG or IgM information available at baseline, were included in the study (Cohort 1).

View Article and Find Full Text PDF

Glucose-regulated protein 78 kDa (GRP78), a key marker of endoplasmic reticulum stress (ERS), is upregulated in hepatocellular carcinoma (HCC) tissues, but its role in hepatitis B virus (HBV)-induced tumorigenesis remains unclear. This study aimed to investigate the contribution of GRP78 to HBV-associated tumor development and explore the ERS pathways involved. The results showed that increased GRP78 expression in patients with HBV-related HCC was associated with a poor prognosis within the first 2 years following diagnosis.

View Article and Find Full Text PDF

Immunotherapy-induced hepatitis is a well-known and relatively common side effect of immune checkpoint inhibitors. It is usually mild to moderate and responds well to corticosteroids with a full recovery. However, in rare cases, severe liver injury may develop, leading to fulminant liver failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!